F
Fanny L. Cherblanc
Researcher at Imperial College London
Publications - 12
Citations - 391
Fanny L. Cherblanc is an academic researcher from Imperial College London. The author has contributed to research in topics: Vibrational circular dichroism & Histone methyltransferase. The author has an hindex of 8, co-authored 10 publications receiving 329 citations.
Papers
More filters
Journal ArticleDOI
Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases.
TL;DR: It is concluded that chaetocin, or related natural products, are not fit for application as selective chemical probes of HKMT function, and the disulfide bridge of the ETP unit is central to chaetOCin’s HKMT inhibitory activity by a nonspecific mechanism.
Journal ArticleDOI
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
Edward Curry,Ian Green,Nadine Chapman-Rothe,Elham Shamsaei,Sarah Kandil,Fanny L. Cherblanc,Luke Payne,Emma Bell,Thota Ganesh,Nitipol Srimongkolpithak,Joachim Caron,Fengling Li,Anthony G. Uren,James P. Snyder,Masoud Vedadi,Matthew J. Fuchter,Robert S. Brown +16 more
TL;DR: It is demonstrated that dual inhibition of EZH2 and EHMT2 is more effective at eliciting biological responses of gene transcription and cancer cell growth inhibition compared to inhibition of single HKMTs, and the first dual EZh2-EHMT1/2 substrate competitive inhibitors that are functional in cells are reported.
Journal ArticleDOI
On the histone lysine methyltransferase activity of fungal metabolite chaetocin.
Fanny L. Cherblanc,Kathryn L. Chapman,Jim Reid,Aaron J. Borg,Sandeep Sundriyal,Laura Alcazar-Fuoli,Elaine Bignell,Marina Demetriades,Christopher J. Schofield,Peter A. DiMaggio,Robert S. Brown,Matthew J. Fuchter +11 more
TL;DR: It is revealed that only the structurally unique ETP core is required for inhibition, and such inhibition is time-dependent and irreversible (in the absence of DTT), ultimately resulting in protein denaturation.
Journal ArticleDOI
Perspectives on natural product epigenetic modulators in chemical biology and medicine.
Fanny L. Cherblanc,Robert W. M. Davidson,Paolo Di Fruscia,Nitipol Srimongkolpithak,Matthew J. Fuchter +4 more
TL;DR: This review will give a perspective on the current status of natural product epigenetic modulators, highlighting the limitations, challenges and opportunities for currently identified molecules, as well as potential strategies for novel compound discovery moving forward.
Journal ArticleDOI
Current limitations and future opportunities for epigenetic therapies
TL;DR: Crystallographic studies on histone lysine methyl transferases provide insights into their mechanism and specificity crucial for the design and development of small-molecule inhibitors, believed to be a highly promising epigenetic target which has yet to be clinically exploited.